Long-term subcutaneous administration of NPY could induce cardiac dysfunction and cardiac hypertrophy in rats, and NPY treatment could also induce hypertrophy of cardiomyocytes in vitro (Chen et al., 2005; Zhang et al., 2015). Here, NPY is linked to cardiac hypertrophy.